142 related articles for article (PubMed ID: 28646517)
1. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.
Jain P; Kantarjian H; Jain N; Short NJ; Yin CC; Kanagal-Shamanna R; Khoury J; Konopleva M; Sasaki K; Kadia TM; Garris R; Pierce S; Estrov Z; Wierda W; Cortes J; O'Brien S; Ravandi F; Jabbour E
Am J Hematol; 2017 Oct; 92(10):E595-E597. PubMed ID: 28646517
[No Abstract] [Full Text] [Related]
2. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
Jain P; Kantarjian H; Ravandi F; Thomas D; O'Brien S; Kadia T; Burger J; Borthakur G; Daver N; Jabbour E; Konopleva M; Cortes J; Pemmaraju N; Kelly MA; Cardenas-Turanzas M; Garris R; Faderl S
Leukemia; 2014 Apr; 28(4):973-5. PubMed ID: 24157581
[No Abstract] [Full Text] [Related]
3. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
4. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
6. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
[TBL] [Abstract][Full Text] [Related]
7. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic analysis of adult patients with T-cell lymphoblastic lymphoma treated with hyper-CVAD.
Kato H; Yamamoto K; Kodaira T; Higuchi Y; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Hematology; 2018 Mar; 23(2):83-88. PubMed ID: 28778131
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
11. Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen.
Luskin MR; Roy DB; Wasik MA; Loren AW
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e55-8. PubMed ID: 24393621
[No Abstract] [Full Text] [Related]
12. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
13. Primary T-cell lymphoblastic lymphoma of the cavernous sinus.
Sadruddin S; Medeiros LJ; DeMonte F
J Neurosurg Pediatr; 2010 Jan; 5(1):94-7. PubMed ID: 20043743
[TBL] [Abstract][Full Text] [Related]
14. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
15. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
[TBL] [Abstract][Full Text] [Related]
16. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.
Sakhdari A; Thakral B; Loghavi S; Kanagal-Shamanna R; Yin CC; Zuo Z; Routbort MJ; Luthra R; Medeiros LJ; Wang SA; Patel KP; Ok CY
Cancer Med; 2020 Feb; 9(3):849-858. PubMed ID: 31804006
[TBL] [Abstract][Full Text] [Related]
17. The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.
Seshadri T; Hourigan MJ; Wolf M; Mollee PN; Seymour JF
Leuk Res; 2006 Apr; 30(4):483-5. PubMed ID: 16171861
[TBL] [Abstract][Full Text] [Related]
18. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI
J Clin Oncol; 2001 Feb; 19(3):750-5. PubMed ID: 11157027
[TBL] [Abstract][Full Text] [Related]
19. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group.
Hastings C; Gaynon PS; Nachman JB; Sather HN; Lu X; Devidas M; Seibel NL
Br J Haematol; 2015 Feb; 168(4):533-46. PubMed ID: 25308804
[TBL] [Abstract][Full Text] [Related]
20. G80A Single Nucleotide Polymorphism in Reduced Folate Carrier-1 Gene in a Mexican Population and its Impact on Survival in Patients with Acute Lymphoblastic Leukemia.
Candelaria M; Ojeda J; Gutiérrez-Hernández O; Taja-Chayeb L; Vidal-Millán S; Dueñas-González A
Rev Invest Clin; 2016; 68(3):154-62. PubMed ID: 27409003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
